Xiaoyu Xu focuses her practice in the areas of initial public offerings, venture capital investment, mergers and acquisitions, and general corporate matters.
ImmuneOnco Biopharmaceuticals – HK$319 Million IPO
September 5, 2023
Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.
Laekna Announces Largest 18A IPO Year to Date at HK$791 Million
June 29, 2023
Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.
IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon
June 14, 2023
Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.
Zion Pharma Announces Sale of Lead Program to Roche
May 15, 2023
Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche.
Cooley advised InnoRNA in its worldwide strategic collaboration with BeiGene to leverage InnoRNA’s innovative technology platform for developing mRNA-based therapeutics. Under the terms of the agreement, InnoRNA will receive an upfront cash payment and will be eligible to receive additional payments based upon the achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties, for the mRNA-LNP research collaboration programs. BeiGene will hold exclusive global development and commercialization rights for the mRNA-LNP therapies jointly discovered by InnoRNA and BeiGene. Financials were not publicly disclosed.
